Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -4 of 4
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
10/1/1990
1.
Phase I Study of Murine Anti-GD2 Ganglioside Monoclonal Antibody 14G2A in Patients with Metastatic Malignant Melanoma, Small Cell Carcinoma of the Lung, Osteosarcoma, or Neuroblastoma (Summary Last Modified 10/90)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
physiologic 70 or less
MDA-DM-88141
NCI-B88-0015, B88-0015
Last Modified:
5/1/1991
2.
Phase Ia/Ib Study of Murine Monoclonal Anti-GD2 Antibody 14G2a in Patients with Metastatic Melanoma and Small Cell Carcinoma of the Lung (Summary Last Modified 05/91)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
UAC-164
NCI-B88-0014, B88-0014
Last Modified:
2/1/1994
3.
Phase I/IB Trial of Murine Monoclonal Anti-GD2 Antibody 14G2A plus IL-2, with or without GM-CSF, in Children with Refractory Neuroblastoma or Melanoma (Summary Last Modified 02/94)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
21 and under
NCI
CCG-0901
Last Modified:
12/1/1993
4.
Phase I Study of MOAB 14.G2A plus IL-2 in Patients with Refractory Melanoma (Summary Last Modified 12/93)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
WCCC-CO-9292
NCI-B91-0011, B91-0011
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute